Clinical Trials Logo
  1. Home
  2. Carcinoid Tumors
  3. NCT02575300

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Carcinoid Tumors Clinical Trial

Official title:
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Clinical Trial Summary

This is a prospective phase II open-label trial, stratifying patients equally into two cohorts consisting of carcinoid tumors and pancreatic neuroendocrine tumors (pNETs). The purpose of this study is to test any good and bad effects of the study drug called Ibrutinib.

The study population will consist of adult patients with histologically confirmed low to intermediate grade NETs of the GI tract, lungs and unknown primary (carcinoid tumors) or pNETs. All patients must be confirmed to have advanced disease. The study will enroll up to 51 patients in two cohorts (30 carcinoid and 21 pNET patients).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02575300
Study type Interventional
Source H. Lee Moffitt Cancer Center and Research Institute
Contact
Status Completed
Phase Phase 2
Start date October 9, 2015
Completion date November 4, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02441062 - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Phase 2
Completed NCT00580320 - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Phase 1
Active, not recruiting NCT02441088 - Theranostics: 68GaDOTATOC and 90YDOTATOC Phase 2
Terminated NCT00227136 - Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Phase 3
Terminated NCT00947167 - A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Phase 2
Terminated NCT02177773 - GA-68 DOTA-TOC of Somatostatin Positive Malignancies Phase 1/Phase 2
Active, not recruiting NCT02795858 - A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Phase 2
Terminated NCT02859064 - Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Phase 2
Active, not recruiting NCT01731925 - A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Phase 2
Completed NCT00088595 - Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Phase 2
Completed NCT01619865 - Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors Phase 1/Phase 2
Completed NCT01253161 - Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Phase 2
Terminated NCT02359500 - 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) Phase 1
Not yet recruiting NCT01373736 - 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Phase 3
No longer available NCT01980732 - 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors N/A